A detailed history of Mml Investors Services, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Mml Investors Services, LLC holds 34,450 shares of ALT stock, worth $244,939. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,450
Previous 47,709 27.79%
Holding current value
$244,939
Previous $317,000 33.12%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$5.5 - $8.1 $72,924 - $107,397
-13,259 Reduced 27.79%
34,450 $212,000
Q2 2024

Aug 14, 2024

BUY
$5.91 - $10.23 $62,380 - $107,977
10,555 Added 28.41%
47,709 $317,000
Q1 2024

May 14, 2024

BUY
$8.22 - $13.81 $59,471 - $99,915
7,235 Added 24.18%
37,154 $378,000
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $18,934 - $102,813
8,848 Added 41.99%
29,919 $337,000
Q3 2023

Nov 14, 2023

SELL
$2.4 - $3.45 $4,183 - $6,013
-1,743 Reduced 7.64%
21,071 $55,000
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $2,325 - $4,023
674 Added 3.04%
22,814 $81,000
Q1 2023

May 12, 2023

BUY
$4.19 - $16.83 $8,945 - $35,932
2,135 Added 10.67%
22,140 $93,000
Q4 2022

Feb 13, 2023

BUY
$8.74 - $16.45 $43 - $82
5 Added 0.03%
20,005 $329,000
Q4 2021

Feb 14, 2022

SELL
$8.69 - $12.48 $1,920 - $2,758
-221 Reduced 1.09%
20,000 $183,000
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $379 - $756
45 Added 0.22%
20,221 $229,000
Q2 2021

Aug 13, 2021

BUY
$9.85 - $16.46 $1,733 - $2,896
176 Added 0.88%
20,176 $199,000
Q1 2021

May 14, 2021

BUY
$12.71 - $24.31 $254,200 - $486,200
20,000 New
20,000 $283,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $349M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Mml Investors Services, LLC Portfolio

Follow Mml Investors Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mml Investors Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mml Investors Services, LLC with notifications on news.